| Kv1. 3 channels are a therapeutic target for T cell-mediated autoimmune diseases C Beeton, H Wulff, NE Standifer, P Azam, KM Mullen, MW Pennington, ... Proceedings of the National Academy of Sciences 103 (46), 17414-17419, 2006 | 608 | 2006 |
| K+ channels as targets for specific immunomodulation KG Chandy, H Wulff, C Beeton, M Pennington, GA Gutman, MD Cahalan Trends in pharmacological sciences 25 (5), 280-289, 2004 | 556 | 2004 |
| The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS H Wulff, PA Calabresi, R Allie, S Yun, M Pennington, C Beeton, ... The Journal of clinical investigation 111 (11), 1703-1713, 2003 | 549 | 2003 |
| Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis C Beeton, H Wulff, J Barbaria, O Clot-Faybesse, M Pennington, D Bernard, ... Proceedings of the national academy of sciences 98 (24), 13942-13947, 2001 | 442 | 2001 |
| ShK-Dap22, a potent Kv1. 3-specific immunosuppressive polypeptide K Kalman, MW Pennington, MD Lanigan, A Nguyen, H Rauer, V Mahnir, ... Journal of Biological Chemistry 273 (49), 32697-32707, 1998 | 345 | 1998 |
| Targeting effector memory T cells with a selective peptide inhibitor of Kv1. 3 channels for therapy of autoimmune diseases C Beeton, MW Pennington, H Wulff, S Singh, D Nugent, G Crossley, ... Molecular pharmacology 67 (4), 1369-1381, 2005 | 341 | 2005 |
| Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease S Rangaraju, EB Dammer, SA Raza, P Rathakrishnan, H Xiao, T Gao, ... Molecular neurodegeneration 13, 1-25, 2018 | 307 | 2018 |
| Peptide therapeutics from venom: Current status and potential MW Pennington, A Czerwinski, RS Norton Bioorganic & medicinal chemistry 26 (10), 2738-2758, 2018 | 278 | 2018 |
| K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity H Wulff, HG Knaus, M Pennington, KG Chandy The Journal of Immunology 173 (2), 776-786, 2004 | 265 | 2004 |
| Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases V Chi, MW Pennington, RS Norton, EJ Tarcha, LM Londono, ... Toxicon 59 (4), 529-546, 2012 | 257 | 2012 |
| The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites AF Kisselev, M Garcia-Calvo, HS Overkleeft, E Peterson, MW Pennington, ... Journal of Biological Chemistry 278 (38), 35869-35877, 2003 | 255 | 2003 |
| Bass hepcidin synthesis, solution structure, antimicrobial activities and synergism, and in vivo hepatic response to bacterial infections X Lauth, JJ Babon, JA Stannard, S Singh, V Nizet, JM Carlberg, ... Journal of Biological Chemistry 280 (10), 9272-9282, 2005 | 251 | 2005 |
| Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1. 3 channel block MP Matheu, C Beeton, A Garcia, V Chi, S Rangaraju, O Safrina, ... Immunity 29 (4), 602-614, 2008 | 244 | 2008 |
| Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone JE Tudor, PK Pallaghy, MW Pennington, RS Norton Nature structural biology 3 (4), 317-320, 1996 | 218 | 1996 |
| Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin H Rauer, M Pennington, M Cahalan, KG Chandy Journal of Biological Chemistry 274 (31), 21885-21892, 1999 | 174 | 1999 |
| Three-dimensional structure in solution of the calcium channel blocker ω-conotoxin PK Pallaghy, BM Duggan, MW Pennington, RS Norton Journal of molecular biology 234 (2), 405-420, 1993 | 162 | 1993 |
| Engineering a stable and selective peptide blocker of the Kv1. 3 channel in T lymphocytes MW Pennington, C Beeton, CA Galea, BJ Smith, V Chi, KP Monaghan, ... Molecular pharmacology 75 (4), 762-773, 2009 | 159 | 2009 |
| Durable pharmacological responses from the peptide ShK-186, a specific Kv1. 3 channel inhibitor that suppresses T cell mediators of autoimmune disease EJ Tarcha, V Chi, EJ Muñoz-Elías, D Bailey, LM Londono, SK Upadhyay, ... Journal of Pharmacology and Experimental Therapeutics 342 (3), 642-653, 2012 | 142 | 2012 |
| A novel fluorescent toxin to detect and investigate Kv1. 3 channel up-regulation in chronically activated T lymphocytes C Beeton, H Wulff, S Singh, S Botsko, G Crossley, GA Gutman, ... Journal of Biological Chemistry 278 (11), 9928-9937, 2003 | 139 | 2003 |
| Structure-guided transformation of charybdotoxin yields an analog that selectively targets Ca2+-activated over voltage-gated K+ channels H Rauer, MD Lanigan, MW Pennington, J Aiyar, S Ghanshani, ... Journal of Biological Chemistry 275 (2), 1201-1208, 2000 | 135 | 2000 |
